VitiligoPhase 4Nb-UVBNCT07174024
A Comparative Study on the Efficacy of Blue Light Emitting Diodes Therapy Versus Targeted Narrow Band UVB in Stable Non-segmental Vitiligo Patients.
A Phase 4 study testing Narrow Band UVB Treatment and blue light emitting diode in people with Vitiligo, run by Cairo University at 1 site in Egypt.
Trial summary
A comparative study on the efficacy of blue light emitting diodes therapy versus targeted Narrow band UVB in stable non-segmental vitiligo patients. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Vitiligo
- What is being tested?
- Narrow Band UVB Treatment and blue light emitting diode
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteEgypt
- Study dates
- 20 Jan 2025to 23 Aug 2025
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- All age group.
- Both genders.
- Subjects with stable non-segmental vitiligo (≥2 patches) acral or non-acral patches of diameter ≤ 2cm.
Who cannot join
- Prior treatment with laser therapies for at least 3 months
- Recent exfoliation procedures.
- Recent surgical procedures.
- Poor skin conditions including keloids.
- Hypersensitivity to light ( visible and near-infrared).
- Medications that make users more sensitive to light.
Show all 10Show fewer
- Anticoagulant and immunosuppressive treatments.
- Gestations or breastfeeding.
- A personal or family history of skin cancer.
- Unstable vitiligo (older lesions have not progressed for the last 1 years and lack of Koebner phenomena ).
Trial locations and contacts
1 site in 1 country.
About this study
A comparative study on the efficacy of blue light emitting diodes therapy versus targeted Narrow band UVB in stable non-segmental vitiligo patients.
Read the detailed description
A comparative study on the efficacy of blue light emitting diodes therapy versus targeted Narrow band UVB in stable non-segmental vitiligo patients.
- Conditions
- Vitiligo
- Being tested
- Narrow Band UVB Treatment, blue light emitting diode
- Keywords
- blue light emitting diode
- Medical subject headings
- Vitiligo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Narrow Band UVB TreatmentDevice
type of phototherapy
blue light emitting diodeDevice
type of diode
| Study group | Role | What they receive |
|---|---|---|
| patients will receive NB-UVB phototherapy sessions on a Randomly selected patch | Active comparator | patients will receive NB-UVB phototherapy sessions on a Randomly selected patch Receives: Device: Narrow Band UVB Treatment |
| Patients will receive blue light emitting diodes phototherapy on a randomly selected patch | Active comparator | Patients will receive blue light emitting diodes phototherapy on a randomly selected patch Receives: Device: blue light emitting diode |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assess the degree of improvement in vitiligo pigmentation using VASI scores before and after treatment.
Assess the degree of improvement in vitiligo pigmentation using VASI scores before and after treatment.
Measured: 48 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2025
- Study start20 Jan 2025
- Primary completion20 May 2025
- Study completion23 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for VitiligoStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nahla Maher Mahmoud Mahran, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07174024
- Sponsor's protocol ID
- MS-92-2025
- Acronym
- Nb-UVB
- Status last verified
- Sep 2025
- First submitted
- 8 Sep 2025
- Last updated
- 15 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Comparative Study on the Efficacy of Blue Light Emitting Diodes Therapy Versus Targeted Narrow Band UVB in Stable Non-segmental Vitiligo Patients.
- ClinicalTrials.gov ID
- NCT07174024
- Acronym / sponsor ID
- Nb-UVB / MS-92-2025
- Conditions
- Vitiligo
- Keywords
- blue light emitting diode
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 20 Jan 2025 (actual)
- Primary completion
- 20 May 2025 (actual)
- Study completion
- 23 Aug 2025 (actual)
- First posted
- 15 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A comparative study on the efficacy of blue light emitting diodes therapy versus targeted Narrow band UVB in stable non-segmental vitiligo patients.
Detailed description
A comparative study on the efficacy of blue light emitting diodes therapy versus targeted Narrow band UVB in stable non-segmental vitiligo patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| patients will receive NB-UVB phototherapy sessions on a Randomly selected patch | Active comparator | Device: Narrow Band UVB Treatmentpatients will receive NB-UVB phototherapy sessions on a Randomly selected patch |
| Patients will receive blue light emitting diodes phototherapy on a randomly selected patch | Active comparator | Device: blue light emitting diodePatients will receive blue light emitting diodes phototherapy on a randomly selected patch |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- All age group.
Key exclusion criteria (10 listed)
- Prior treatment with laser therapies for at least 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Narrow Band UVB Treatmenttype of phototherapy | Device | patients will receive NB-UVB phototherapy sessions on a Randomly selected patch |
| blue light emitting diodetype of diode | Device | Patients will receive blue light emitting diodes phototherapy on a randomly selected patch |
Primary outcome
Assess the degree of improvement in vitiligo pigmentation using VASI scores before and after treatment.
Time frame: 48 weeks
Assess the degree of improvement in vitiligo pigmentation using VASI scores before and after treatment.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Vitiligo
Not yet recruitingPhase 2/3
Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo
Vitiligo
RecruitingPhase 2
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Vitiligo, Non-Segmental Vitiligo (NSV)
Active, not recruitingPhase 2
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
Nonsegmental Vitiligo
Active, not recruiting
Plasma Exeresis Plus NB-UVB Versus NB-UVB Alone for Stable Vitiligo
Vitiligo
RecruitingPhase 2
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
Non-segmental Vitiligo
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Narrow Band UVB Treatment and blue light emitting diode in people with Vitiligo, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assess the degree of improvement in vitiligo pigmentation using VASI scores before and after treatment. (time frame: 48 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2025.